35 related articles for article (PubMed ID: 31587337)
21. Bivalirudin as a substitute for heparin in neurointervention for patients with heparin-induced thrombocytopenia.
Sukumaran M; Cantrell DR; D'Agostino C; Jahromi BS; Ansari SA; Potts MB
J Stroke Cerebrovasc Dis; 2024 Jun; 33(6):107310. PubMed ID: 38636321
[TBL] [Abstract][Full Text] [Related]
22. Bivalirudin: a direct thrombin inhibitor.
Gladwell TD
Clin Ther; 2002 Jan; 24(1):38-58. PubMed ID: 11833835
[TBL] [Abstract][Full Text] [Related]
23. Bivalirudin.
Warkentin TE; Greinacher A; Koster A
Thromb Haemost; 2008 May; 99(5):830-9. PubMed ID: 18449412
[TBL] [Abstract][Full Text] [Related]
24. Direct thrombin inhibition during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia.
Lewis BE; Hursting MJ
Expert Rev Cardiovasc Ther; 2007 Jan; 5(1):57-68. PubMed ID: 17187457
[TBL] [Abstract][Full Text] [Related]
25. Combined Use of Bivalirudin and Radial Access in Acute Coronary Syndromes Is Not Superior to the Use of Either One Separately: Meta-Analysis of Randomized Controlled Trials.
Mina GS; Gobrial GF; Modi K; Dominic P
JACC Cardiovasc Interv; 2016 Aug; 9(15):1523-31. PubMed ID: 27491601
[TBL] [Abstract][Full Text] [Related]
26. A Review of Bivalirudin for Pediatric and Adult Mechanical Circulatory Support.
Taylor T; Campbell CT; Kelly B
Am J Cardiovasc Drugs; 2021 Jul; 21(4):395-409. PubMed ID: 33174088
[TBL] [Abstract][Full Text] [Related]
27. Autoimmune heparin-induced thrombocytopenia and venous limb gangrene after aortic dissection repair: in vitro and in vivo effects of intravenous immunoglobulin.
Arcinas LA; Manji RA; Hrymak C; Dao V; Sheppard JI; Warkentin TE
Transfusion; 2019 Jun; 59(6):1924-1933. PubMed ID: 30903805
[TBL] [Abstract][Full Text] [Related]
28. Direct-Thrombin Inhibitor Utilization in Patients With Heparin-Induced Thrombocytopenia and Undergoing Catheter-Directed Thrombolysis: A Summary of Published Case Reports.
Badreldin HA; Albassam G; Aldoughaim M; Alyami M
J Cardiovasc Nurs; 2019; 34(3):244-249. PubMed ID: 30543545
[TBL] [Abstract][Full Text] [Related]
29. Risk Factors and Outcomes Associated with Prolonged Subtherapeutic Anticoagulation with Bivalirudin: A Retrospective Cohort Study.
Orzel LA; Abel EE; Blais DM; Wang TF; Porter KA; Burcham PK
Pharmacotherapy; 2019 Dec; 39(12):1157-1166. PubMed ID: 31587337
[TBL] [Abstract][Full Text] [Related]
30. Impact of anticoagulation strategy with bivalirudin or heparin on nonaccess site bleeding in percutaneous coronary interventions: A meta-analysis of randomized trials.
Verdoia M; Barbieri L; Parodi G; Bellandi B; Schaffer A; Suryapranata H; De Luca G
Catheter Cardiovasc Interv; 2017 Oct; 90(4):553-565. PubMed ID: 28471057
[TBL] [Abstract][Full Text] [Related]
31. Bivalirudin for Pediatric Procedural Anticoagulation: A Narrative Review.
Zaleski KL; DiNardo JA; Nasr VG
Anesth Analg; 2019 Jan; 128(1):43-55. PubMed ID: 29461391
[TBL] [Abstract][Full Text] [Related]
32. Effect of post-primary percutaneous coronary intervention bivalirudin infusion on net adverse clinical events and mortality: A comprehensive pairwise and network meta-analysis of randomized controlled trials.
Shah R; Matin K; Rogers KC; Rao SV
Catheter Cardiovasc Interv; 2017 Aug; 90(2):196-204. PubMed ID: 27862911
[TBL] [Abstract][Full Text] [Related]
33. Comparison of heparin, bivalirudin, and different glycoprotein IIb/IIIa inhibitor regimens for anticoagulation during percutaneous coronary intervention: A network meta-analysis.
Lipinski MJ; Lee RC; Gaglia MA; Torguson R; Garcia-Garcia HM; Pichard AD; Satler LF; Waksman R
Cardiovasc Revasc Med; 2016 Dec; 17(8):535-545. PubMed ID: 27842901
[TBL] [Abstract][Full Text] [Related]
34. Bivalirudin for Alternative Anticoagulation in Extracorporeal Membrane Oxygenation: A Systematic Review.
Sanfilippo F; Asmussen S; Maybauer DM; Santonocito C; Fraser JF; Erdoes G; Maybauer MO
J Intensive Care Med; 2017 Jun; 32(5):312-319. PubMed ID: 27356945
[TBL] [Abstract][Full Text] [Related]
35.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [New Search]
